Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masakazu Fujio is active.

Publication


Featured researches published by Masakazu Fujio.


Nuclear Medicine and Biology | 2002

Synthesis and evaluation of 11C-labeled (S)-N-{[1-(2-phenylethyl) pyrrolidin-2-yl]methyl}-3-methylthiobenzamide as a PET 5-HT1A receptor ligand

Masakazu Fujio; Shinji Nagata; Kazunori Kawamura; Naoki Sugiyama; Hiroshi Tanaka; Kimiichi Uno; Kiichi Ishiwata

Abstract We prepared 5-HT 1A receptor ligands ( S )- N -{[1-(2-phenylethyl)pyrrolidin-2-yl]methyl}-3-[ 11 C]methylthiobenzamide ([ 11 C]( S )-PPMMB) (Ki = 4.3 nM) and the less active [ 11 C]( R )-PPMMB (Ki = 160 nM) by reduction of the disulfide dimer and subsequent [ 11 C]methylation of demethyl ( S )- and ( R )-PPMMB, respectively. Both radioligands showed similar brain distribution in mice with relatively higher affinity for the hippocampus being rich in 5-HT 1A receptors than for other brain regions. Uptake of [ 11 C]( S )-PPMMB was not reduced by carrier-loading nor by pretreatment with 5-HT 1A receptor ligands. [ 11 C]( S )-PPMMB is therefore not a suitable radioligand for mapping 5-HT 1A receptors using positron emission tomography.


Bioorganic & Medicinal Chemistry Letters | 2000

N-[1-(2-phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists

Masakazu Fujio; Takanobu Kuroita; Yoko Sakai; Haruto Nakagawa; Yasuhiro Matsumoto

A series of 1-adamantanecarboxamides was synthesized and examined for their potency as a selective 5-HT2 receptor antagonist. We found (S)-N-[1-[2-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-1-adamantane carboxamide hydrochloride hydrate (10-(S), Y-39241) to have a high affinity and selectivity for 5-HT2 receptors, and this potent anti-platelet effect of Y-39241 was confirmed both in vitro and in vivo.


Bioorganic & Medicinal Chemistry Letters | 2000

N-{[1-(2-phenylethyl)pyrrolidin-2-yl]methyl}cyclohexane-carboxamides as selective 5-HT1A receptor agonists

Masakazu Fujio; Yoshifumi Togo; Hideo Tomozane; Takanobu Kuroita; Yasunori Morio; Jiro Katayama; Yasuhiro Matsumoto

A series of benzamides was synthesized as selective agonists for the 5-HT1A receptor. It was found that (S)-N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarb oxamide(7-(S)) has potent and selective agonistic activity for the 5-HT1A receptor (5-HT1A; Ki 0.49 nmol/L, D2; IC50 = >1000 nmol/L, 5-HT2; Ki = 240 nmol/L).


Archive | 2002

Fused heterocyclic compound and medicinal use thereof

Masakazu Fujio; Hiroyuki Satoh; Atsushi Numata; Shinichi Takanashi; Yasuhiro Egi; Ryou Tatsumi


Journal of Medicinal Chemistry | 2006

(R)-3‘-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5‘-oxazolidin]-2‘-one, a Novel and Potent α7 Nicotinic Acetylcholine Receptor Partial Agonist Displays Cognitive Enhancing Properties

Ryo Tatsumi; Masakazu Fujio; Shinichi Takanashi; Atsushi Numata; Jiro Katayama; Hiroyuki Satoh; Yasuyuki Shiigi; Junichi Maeda; Makoto Kuriyama; Takashi Horikawa; Takahiro Murozono; Kenji Hashimoto; Hiroshi Tanaka


Archive | 1999

Pyrrolidine compounds and medicinal utilization thereof

Takanobu Kuroita; Masakazu Fujio; Haruto Nakagawa


Journal of Medicinal Chemistry | 2005

Discovery of the α7 Nicotinic Acetylcholine Receptor Agonists. (R)-3‘-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5‘-[1‘,3‘]oxazolidin-2‘-one as a Novel, Potent, Selective, and Orally Bioavailable Ligand

Ryo Tatsumi; Masakazu Fujio; Hiroyuki Satoh; Jiro Katayama; Shinichi Takanashi; Kenji Hashimoto; Hiroshi Tanaka


Archive | 1997

Fused heterocyclic compounds and medicinal uses thereof

Takanobu Kuroita; Yoshifumi Togo; Seigo Ishibuchi; Masakazu Fujio; Takashi Futamura


Archive | 2000

1-AZABICYCLOALKANE COMPOUND AND PHARMACEUTICAL USE THEREOF

Masakazu Fujio; Kenji Hashimoto; Jiro Katayama; Atsushi Numata; 謙二 橋本; 敦 沼田; 二郎 片山; 雅和 藤尾


Archive | 2001

Spiro compounds, process for preparing the same and use thereof as drugs

Masakazu Fujio; Kenji Hashimoto; Jiro Katayama; Atsushi Numata

Collaboration


Dive into the Masakazu Fujio's collaboration.

Top Co-Authors

Avatar

Takanobu Kuroita

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroyuki Satoh

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yasuhiro Egi

Mitsubishi Tanabe Pharma

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shinya Inoue

Mitsubishi Tanabe Pharma

View shared research outputs
Researchain Logo
Decentralizing Knowledge